Abemaciclib mesylate (LY2835219)

目录号:S7158 中文名称:甲磺酸阿贝西尼

仅限科研使用

Abemaciclib (LY2835219)是一种有效的,选择性CDK4CDK6抑制剂,无细胞试验中IC50分别为2 nM和10 nM。Phase 3。

Abemaciclib mesylate (LY2835219) Chemical Structure

CAS: 1231930-82-7

规格 价格 库存 购买数量
10mM (1mL in DMSO) RMB 4644.52 现货
RMB 2203.44 现货
RMB 3333.88 现货
RMB 6544.35 现货
大包装 有超大折扣
大剂量询单有大折扣!

今日订购,明日送达 全国免运费 分装免费 分装成小规格产品(单支最小为1mg)
如1支10mg产品可分装为10支1mg产品

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Abemaciclib mesylate (LY2835219)发表文献67篇:

产品安全说明书

CDK抑制剂选择性比较

相关CDK产品

生物活性

产品描述 Abemaciclib (LY2835219)是一种有效的,选择性CDK4CDK6抑制剂,无细胞试验中IC50分别为2 nM和10 nM。Phase 3。
靶点
CDK4 [1]
(Cell-free assay)
CDK6 [1]
(Cell-free assay)
2 nM 10 nM
体外研究

LY2835219是一种口服有效的细胞周期蛋白依赖性激酶(CDK)抑制剂,靶向作用于CDK4(cyclin D1)和CDK6(cyclin D3)细胞周期通路,具有潜在的抗肿瘤活性。LY2835219特异性抑制CDK4和6,从而在早G1期抑制视网膜母细胞瘤(Rb)蛋白磷酸化。抑制Rb磷酸化,防止CDK-介导的G1-S期转换,从而使细胞周期停滞在G1期,抑制DNA合成,且抑制癌细胞生长。某些类型的癌症中丝/苏氨酸激酶CDK4/6的过表达,导致细胞周期调节失控。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human COLO205 cells M4j5SWZ2dmO2aX;uJIF{e2G7 NFPKb5czPCCq M4rHTGlvcGmkaYTpc44hd2ZiQ1TLOE83KGmwIHj1cYFvKEORTF:yNFUh[2WubIOgZZN{\XO|ZXSgZZMhdWG6aX31cUBk\WyuIHP5Z4xmKGG{cnXzeEBifCCJMTDwbIF{\SCjZoTldkAzPCCqcoOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcI94KGO7dH;t[ZRzcWNiYX7hcJl{cXN? MlrTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMUW1O|EoRjJ4MUG1OVcyRC:jPh?=
human COLO205 cells NFXGOZFHfW6ldHnvckBie3OjeR?= MUWyOEBp NVn5dHBLUW6qaXLpeIlwdiCxZjDDSGs1NzZiaX6gbJVu[W5iQ1;MU|IxPSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHJjKHCqb4PwbI9zgWyjdHnvckBi\nSncjCyOEBpenNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCuYYPldk1{[2Gwbnnu[{BndHWxcnXzZ4Vv[2VibXnjdo9xdGG2ZTDjfZRwdWW2cnnjJIFv[Wy7c3nz NF\MZ3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGxOVU4OSd-Mk[xNVU2PzF:L3G+
insect cells  NXvtc4RkTnWwY4Tpc44h[XO|YYm= NY\kb3dGPTBibXnudy=> MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGNFUzRxY4njcIlvKERzIHX4dJJme3OnZDDpckBqdnOnY4SgZ4VtdHNiYYPz[ZN{\WRiYYOgdIhwe3Cqb4L5cIF1cW:wIH;mJGNVWkZiYX\0[ZIhPTBibXnud{BjgSCvaXPyc5Bt[XSnIIPjbY51cWyuYYTpc44h[2:3boTldkwhUUN3ME2yJI5O NXnLcIR4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVU2PzFpPkK2NVE2PTdzPD;hQi=>
insect cells  NF3sXXVHfW6ldHnvckBie3OjeR?= NYXOSGhzPTBibXnudy=> MV7Dc41x\XSrdHn2[UBqdmirYnn0bY9vKG:oIHj1cYFvKEOGS{SvZ5lkdGmwIFSxJIV5eHKnc4Pl[EBqdiCrboPlZ5Qh[2WubIOgZZN{\XO|ZXSgZZMheGixc4Doc5J6dGG2aX;uJI9nKEOWUl[gZYZ1\XJiNUCgcYlveyCkeTDNbYNp[WWuaYOtUYVvfGWwIIDsc5Qh[W6jbInzbZMhcW5icILld4Vv[2Vib3[gRXRRNCCNaU2wMlYhdk1? NF[3TnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGxOVU4OSd-Mk[xNVU2PzF:L3G+
HCT116 NH\LRZpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NULQXXhSPzJiaILz Mm\FTWM2OCB;IECuOVQh|ryP NIjqXJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEG2OVM1OSd-M{CxOlU{PDF:L3G+
MCF7 NXmxOlRCSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NVTPUI5yPzJiaILz MWrJR|UxKD1iMD63NUDPxE1? M{G1NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMU[1N|QyLz5|MEG2OVM1OTxxYU6=
PANC1 M{O1WmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NEfiSms4OiCqcoO= M2fMNWlEPTBiPTC1Mlk1KM7:TR?= MmTMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzNkWzOFEoRjNyMU[1N|QyRC:jPh?=
Sf9 M1fBeWZ2dmO2aX;uJIF{e2G7 NXvjb3E{UW6qaXLpeIlwdiCxZjDDSGsyN0O7Y3zpckBDKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcnHsJIlv\mWldHXkJIlve2WldDDT[lkh[2WubIOgeZNqdmdiaHnzeI9v\SCKMTDhd{B{fWK|dILheIUhcW5icILld4Vv[2Vib3[gX4didW2jLUOzVH1CXFBuIFnDOVAhRSByLkO3NUDPxE1w Ml;qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NEG4OVMoRjJ4N{SxPFU{RC:jPh?=
Sf9 MmjDSpVv[3Srb36gZZN{[Xl? MVy5NEBucW6| NEXkfWpKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIF6teIVzdWmwYXygS3NVNXSjZ3fl[EBETEt2IDi0JJRwKDNyMzDy[ZNq\HWnczmvZ5lkdGmwIFSxJEg1KHSxIEK5OUBz\XOrZIXld{kh\XiycnXzd4VlKGmwIIPmPUBk\WyuczD1d4lv\yCFLYTldo1qdmGuIILleIlvd2KuYYP0c41iKG[{YXft[Y51KGG|IIP1ZpN1emG2ZTDh[pRmeiB7MDDtbY5{KGK7IGvnZY1u[S1|M2DdRXRRKGKjc3XkJI1q[3KxYnX0ZUB{[2mwdHnscIF1cW:wIHPveY51cW5uIFvpJF0hOC5yMEKg{txONg>? NWi2UnJqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexO|ExOzZpPkK3NVcyODN4PD;hQi=>
Sf9 Ml[zSpVv[3Srb36gZZN{[Xl? NHjhfY06OCCvaX7z M{DTWWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSg[pVtdCCuZX7neIghcHWvYX6gUk11\XKvaX7hcEBIW1RvdHHn[4VlKEOGS{[gLFEhfG9iM{K2JJJme2mmdXXzLU9kgWOuaX6gSFEhMDRidH:gNlk2KHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gd4Y6KGOnbHzzJJV{cW6pIFOteIVzdWmwYXygdoV1cW6xYnzhd5RwdWFiZoLh[41mdnRiYYOgd5Vje3S{YYTlJIFnfGW{IEmwJI1qdnNiYomgX4didW2jLUOzVH1CXFBiYnHz[YQhdWmlcn;i[ZRiKHOlaX70bYxt[SxiS3mgQUAxNjBzIN88UU4> NEOwcZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{G3NVA{Pid-MkexO|ExOzZ:L3G+
Sf21 NV62Now5TnWwY4Tpc44h[XO|YYm= NWXHc3BiUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDmeYxtKGynbnf0bEBENXSncn3pcoFtKEirc{[teIFo\2WmIFPET|cw[3mlbHnuJGgwVi22ZYLtbY5idCCJU2SteIFo\2WmIF3BWFEh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJHNnOjFiaX7z[YN1KGOnbHzzJJV{cW6pIHPkb|che3Wkc4TyZZRmKHCncITp[IUtKEurIE2gN{46OSEQvF2u MnvjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzN{GwN|YoRjJ5MUexNFM3RC:jPh?=
COLO205 MXjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NFPPdpE6PiCqcoO= NGTVNlZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPPUG8zODViY3XscJMh[W[2ZYKgPVYhcHK|IHL5JGNEUy16IHHzd4F6NCCLQ{WwJF0hOC52NjFOwG0v MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTB5NEK1OEc,OjlyN{SyOVQ9N2F-
U87MG MkfRRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MYm3NkBpenN? M1PONWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUi3UWch[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFTBVGkhe3SjaX7pcoch[mG|ZXSgZZN{[XluIFnDOVAhRSByLkC0PFEh|ryPLh?= NV3PTW5PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyOFc5PTdpPkK5NlQ4QDV5PD;hQi=>
Sf9 NWfGNZB{TnWwY4Tpc44h[XO|YYm= MmLhTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCQLYTldo1qdmGuIFfTWE11[WepZXSgR2RMPCBqU{SgeI8hTTNyMzDy[ZNq\HWnczmvR5lkdGmwIFSxJEhSPCC2bzDJNlk2KHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gd4Y6KGOnbHzzJJV{cW6pIGLiJJBzd3SnaX6gLFc4OyC2bzC5NlghemW|aXT1[ZMqKGG|IIP1ZpN1emG2ZTDpckBxemW|ZX7j[UBw\iCdM{PQYU1CXFBiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yCvZYToc4QtKEmFNUCgQUAxNjByMjFOwG0v M2LLOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEK5PFMzLz5{OUSyPVg{OjxxYU6=
Sf9 NFXIUWNHfW6ldHnvckBie3OjeR?= MoLtPVAhdWmwcx?= MYfJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKG[3bHygcIVv\3SqIFPET|Yh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJHNnQSCrboPlZ5Qh[2WubIOgeZNqdmdiaHnzeI9v\SCKMTDzeYJ{fHKjdHWgZYZ1\XJiOUCgcYlveyCkeTDBSHAuT2yxIHHzd4F6NCCLQ{WwJF0hOC5yMEe4JO69VS5? MmXKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Mkm4N|IoRjJ7NEK5PFMzRC:jPh?=
Sf9 MXfGeY5kfGmxbjDhd5NigQ>? M37ITWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iTj30[ZJucW6jbDDHV3QufGGpZ3XkJGNFUzRiKF2xJJRwKEF|Mk[gdoV{cWS3ZYOpM2N6[2yrbjDENUApWTRidH:gTVI6PSC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJJNnQSClZXzsd{B2e2mwZzDSZkBxem:2ZXnuJEg4PzNidH:gPVI5KHKnc3nkeYV{MSCjczDzeYJ{fHKjdHWgbY4heHKnc3XuZ4Uhd2ZiW{OzVH0uSVSSIHL5JJNkcW62aXzsZZRqd25iY3;1cpRqdmdibXX0bI9lNCCLQ{WwJF0hOC5yMTFOwG0v MkDaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Mkm4N|IoRjJ7NEK5PFMzRC:jPh?=
Sf9 MkTDSpVv[3Srb36gZZN{[Xl? MWO5NEBucW6| NEG4eXVKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIH\1cIwhdGWwZ4ToJGNFUzFxQ4njcIlvKER|IHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCVZkmgbY5{\WO2IHPlcIx{KHW|aX7nJIhqe3SxbnWgTFEhe3Wkc4TyZZRmKGGodHXyJFkxKG2rboOgZpkhSUSSLVfsc{Bie3OjeTygTWM2OCB;IECuNFU3KM7:TT6= MorYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Mkm4N|IoRjJ7NEK5PFMzRC:jPh?=
MDA-MB-231 M{LXV2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5? MVK3NkBpenN? NXzJb|lFSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCGQWDJJJN1[WmwaX7nJIJie2WmIHHzd4F6NCCLQ{WwJF0hOC5zOUGg{txONg>? M17Gd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEK5PFMzLz5{OUSyPVg{OjxxYU6=
COLO205 NHvQWIxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGw MYC5OkBpenN? MkDaRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCFT1zPNlA2KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDDR2s5KGG|c3H5MEBKSzVyIE2gNE4zOTdizszNMi=> MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR3OUK3OEc,Ojl2NUmyO|Q9N2F-
MDA-MB-468 MnntRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idg>? MWW5OkBpenN? Ml7uRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPRFGtUWIuPDZ6IHPlcIx{KGGodHXyJFk3KGi{czDifUBES0t6IHHzd4F6NCCLQ{WwJF0hPC56MEig{txONg>? NVTnPHJDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OVkzPzRpPkK5OFU6Ojd2PD;hQi=>
COLO205 NET3eW9KdmirYnn0bY9vKG:oIFPET|QhcW5iaIXtZY4> NHiyVpAxNjFidH:gNVAhfU1? M{HmW|I1KGi{cx?= MV;Jcohq[mm2aX;uJI9nKEOGS{SgbY4hcHWvYX6gR29NVzJyNTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hfG:2YXygVoIheHKxdHXpckBt\X[nbDDheEAxNjFidH:gNVAhfU1iYX\0[ZIhOjRiaILzJIJ6KGmvbYXuc4Jtd3S2aX7nJI1mfGixZB?= NHPVfFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS1PVI4PCd-Mkm0OVkzPzR:L3G+
COLO205 NFHBOGdE\WyuIHP5Z4xmKGG|c3H5 NWfHPWxRfXBidH:gNVAhfU1? NXzhSI1VOjRiaILz M4X4[WNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJGNQVE9{MEWgZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IFeyM20heGijc3WgeZAhfG9iMUCgeW0h[W[2ZYKgNlQhcHK|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZoF{\WRiRlHDV{BidmGueYPpdy=> NUL2d|NDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OVkzPzRpPkK5OFU6Ojd2PD;hQi=>
Assay
Methods Test Index PMID
Western blot p-Rb(S780) / Rb / p21 p-ERK / ERK / p-Akt / Akt / p-mTOR(S2448) / mTOR pRb(S795) / E2F1 / Cyclin A2 / Cyclin E2 26909611 27748766
Growth inhibition assay Cell viability 26909611
体内研究 LY2835219-MsOH处理脑的剂量百分比为0.5–3.9%。LY2835219-MsOH处理皮下和颅内胶质瘤模型(U87MG),抑制肿瘤生长,这种作用存在剂量依赖性,不管是单独处理,还是与Temozolomide联用。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度(25°C)

体外

体内

从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
water

100mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 602.7
化学式

C27H32F2N8.CH4O3S

CAS号 1231930-82-7
储存条件 3年 -20°C 粉状
2年 -80°C 溶于溶剂

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量 浓度 体积 分子量

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05169567 Not yet recruiting Drug: Abemaciclib|Drug: Fulvestrant|Drug: Placebo Breast Neoplasm|Neoplasm Metastasis Eli Lilly and Company January 14 2022 Phase 3
NCT04791384 Not yet recruiting Drug: Abemaciclib|Drug: Elacestrant Breast Cancer Criterium Inc. January 1 2022 Phase 1|Phase 2
NCT04967521 Recruiting Drug: Abemaciclib|Drug: Placebo Advanced Dedifferentiated Liposarcoma Sarcoma Alliance for Research through Collaboration|Eli Lilly and Company November 11 2021 Phase 3
NCT04750928 Recruiting Drug: Abemaciclib Neurofibromatosis 1 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) November 29 2021 Phase 1|Phase 2
NCT04941274 Recruiting Drug: Abemaciclib Kaposi Sarcoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) September 29 2021 Phase 1|Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们

常见问题及建议解决方法

问题 1:
Is your product S7158 LY2835219 “mesylate salt form”?

回答:
Our S7158 LY2835219 is mesylate salt form.